Amneal Pharmaceuticals to Acquire Enzon Pharmaceuticals
Ticker: ENZN · Form: 8-K · Filed: Jun 14, 2024 · CIK: 727510
| Field | Detail |
|---|---|
| Company | Enzon Pharmaceuticals, INC. (ENZN) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pharmaceuticals
TL;DR
Amneal buying Enzon, deal expected Q3 2024.
AI Summary
Enzon Pharmaceuticals, Inc. announced on June 10, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuticals LLC. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition will expand Amneal's specialty product portfolio.
Why It Matters
This acquisition signifies a consolidation within the pharmaceutical sector, potentially impacting the availability and pricing of Enzon's products and creating opportunities for Amneal's growth.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Players & Entities
- Enzon Pharmaceuticals, Inc. (company) — Company being acquired
- Amneal Pharmaceuticals LLC (company) — Acquiring company
- June 10, 2024 (date) — Date of the agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Enzon Pharmaceuticals, Inc. has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuticals LLC.
Who is acquiring Enzon Pharmaceuticals?
A subsidiary of Amneal Pharmaceuticals LLC is acquiring Enzon Pharmaceuticals.
When was the agreement to be acquired announced?
The agreement was announced on June 10, 2024.
When is the acquisition expected to close?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-14 16:05:28
Key Financial Figures
- $0.10 — tock price trading at, or in excess of, $0.10 for the period of time that was require
Filing Documents
- tm2417162d1_8k.htm (8-K) — 22KB
- 0001104659-24-071747.txt ( ) — 184KB
- enzn-20240610.xsd (EX-101.SCH) — 3KB
- enzn-20240610_lab.xml (EX-101.LAB) — 33KB
- enzn-20240610_pre.xml (EX-101.PRE) — 22KB
- tm2417162d1_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On June 10, 2024, Enzon Pharmaceuticals, Inc. (the " Company ") was notified by the OTCQX Markets Group (the " OTCQX "), that it had regained compliance with the OTCQX's standards for continued qualification as a result of its stock price trading at, or in excess of, $0.10 for the period of time that was required to regain compliance. Previously, in January 2024, the Company was notified that it no longer met the stock bid price for continued qualification and had until July 15, 2024 to regain compliance with the OTCQX. The Company is currently compliant with the OTCQX continued listing qualifications and no further action is required on the part of the Company.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: June 14, 2024 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary